




3rd
pRED *Discovery Oncology Award*

Penzberg, 29 - 30 October 2015



Welcome to the Roche Innovation Center Penzberg!

It is our pleasure to welcome the finalists and all of you to the 3rd pRED Discovery Oncology Award “Pathophysiology of the extracellular matrix - basic concepts and therapeutic approaches for cancer therapy “.

The Roche Pharma Research and Early Development organization – pRED – consists of some 2,000 scientists and clinicians with a shared vision of excellence in science, a proud heritage of healthcare innovation and a commitment to deliver new and effective medicines to patients. Our vision is to translate scientific imagination and rigor into medical innovation through a diversity of therapeutic modalities and fully leveraging technologies and talent, both internally and externally.

pRED focuses on the therapeutic areas of: Oncology, Neuroscience, Infectious Diseases, Inflammatory Diseases, Ophthalmology and Rare Diseases at six strategic sites worldwide. Oncology is focusing on cancer immunotherapy engaging with the patient’s immune system and molecular targeted therapeutics directed against cancer cells.

Roche in Penzberg, just south of the cosmopolitan city Munich, is one of the largest sites of the Roche Group.

Over 5,500 employees work in research, development and production of Diagnostics and Pharma. The site is one of the largest biotech centers in Europe and an innovation hub for therapeutic proteins.

We look forward to a vibrant scientific exchange and a fun meeting!

Christian Rommel

Global Head of Oncology Discovery

Roche Pharma Research & Early Development

*If we knew what it was we were doing,
it would not be called research, would it?*

Albert Einstein

Agenda:

Thursday, 29 October 2015

Time	Topic	Location	Speaker
All day	Individual Arrival	Landgasthof Osterseen	
14:15 h	Bus transfer to Roche Penzberg <i>Meeting Point: Lobby</i>	Landgasthof Osterseen →Roche Penzberg	
14:45 h	Registration	Roche Penzberg 121 / Foyer 200	
15:10 h	Welcome	Roche Penzberg 121 / 2.305 a&b	Michael Weidner Director Oncology Roche Pharma Research & Early Development
15:15 h	Introduction to innovation hub Penzberg – Biotech from science to patients	Roche Penzberg 121 / 2.305 a&b	Barbara Jopp-Heins Communications Roche Diagnostics GmbH
15:45 h	pRED Oncology	Roche Penzberg 121 / 2.305 a&b	Christian Rommel Global Head of Oncology Discovery Roche Pharma Research & Early Development
16:20 h	Group Picture		
16:30 h	Guided tour - Technical Development	Roche Penzberg 362 / Technikum	Roberto Falkenstein Development Recovery & DSP Pharma Biotech Penzberg
17:30 h	Bus transfer to Landgasthof Osterseen	Roche Penzberg →Landgasthof Osterseen	
19:00 h	Dinner	Landgasthof Osterseen	

Agenda:

Friday, 30 October 2015

Time	Topic	Location	Speaker
08:00 h	Bus transfer to Roche Penzberg <i>Meeting Point: Lobby</i>	Landgasthof Osterseen →Roche Penzberg	
08:00 h	Registration & Welcome Coffee	Roche Penzberg 121 / Foyer 200	
08:15 h	Welcome	Roche Penzberg 121 / 2.305 a&b	Christian Meisel Global Head of Biomarkers and Translational R&D Innovation & Site Head Roche Innovation Center Penzberg
08:30 h	Session I	Roche Penzberg 121 / 2.305 a&b	Chair: Liliana Schäfer University Clinic Frankfurt Germany
08:30 h	Activin promotes skin tumorigenesis via attraction and re-programming of macrophages		Maria Antsifeyeva ETH Zurich Switzerland
09:00 h	Development of a human 3D organotypic lung tumor model with 18FDG-PET as a non-destructive treatment read-out		David Fecher University Hospital Würzburg Germany
09:30 h	ECM derived growth factors regulating tumor progression and metastasis		Lukas Hawinkels Leiden University The Netherlands
10:00 h	Coffee Break	Roche Penzberg 121 / Foyer 200	
10:30 h	Session II	Roche Penzberg 121 / 2.305 a&b	Chair: Sylvie Ricard-Blum University Lyon France
10:30 h	An angiostatic antibody vaccine		Elisabeth Huijbers VU University, Medical Center Cancer Center The Netherlands
11:00 h	Thrombospondin-targeting TAX2 peptide as a new unpredicted anti- cancer agent		Albin Jeanne University of Reims Champagne Ardenne France

Agenda:

Friday, 30 October 2015

Time	Topic	Location	Speaker
11:30 h	The liver's extracellular matrix impacts gene expression in metastatic pancreatic cancer cells		Khamael Majeed Kadhim Al-Taee German Cancer Research Centre Heidelberg Germany
12:00 h	Lunch & Poster session	Roche Penzberg 121 / Foyer 200	
13:00 h	Session III	Roche Penzberg 121 / 2.305 a&b	Chair: Wilhelm Krek ETH Zurich Switzerland
13:00 h	Identification of ECM components inducing human brain tumor initiating cell invasion		Verena Leidgens University of Regensburg Germany
13:30 h	Stromal delivery of long Pentraxin-3 impairs FGF/FGFR-dependent tumor growth and metastasis		Roberto Ronca University of Brescia Italy
14:00 h	Proteomic profiling of metastatic matrisome reveals citrullination as an important marker of colorectal liver metastasis		Arseniy Yuzhalin University of Oxford United Kingdom
14:30 h	Poster Session	Roche Penzberg 121 / Foyer 200	
16:30 h	Coffee Break	Roche Penzberg 121 / Foyer 200	
17:30 h	Bus transfer to Possenhofen <i>Meeting Point: In front of Bldg. 121</i>		
18:00 h	Social Event and Award Ceremony	Forsthaus am See	

General Information:

Airport Munich

Nordallee 25
 85356 München
 Phone: +49 (0) 89 97500
www.munich-airport.de

Landgasthof Osterseen



Hofmark 9
 82393 Iffeldorf
 Phone: +49 (0) 8856 - 928 60
landgasthof@osterseen.de
www.landgasthof-osterseen.de



Restaurant Forsthaus am See



Am See 1
 82343 Possenhofen
 Phone.: +49 (0) 8157 - 930 10
www.forsthaus-am-see.de



Shuttle / Transfers

We will provide a bus shuttle throughout the event. For environmental protection, we kindly ask you to use the shuttle where possible.









Herausgeber

Roche Diagnostics GmbH
Nonnenwald 2
82377 Penzberg, Germany

© 2014

www.roche.com